Does the MTHFD1 rs2236225 (G1958A) variant reduce folate form interconversion and influence homocysteine levels?

The MTHFD1 rs2236225 (G1958A) polymorphism is a significant genetic variant that alters the efficiency of one-carbon metabolism. This variant results in an arginine-to-glutamine (R653Q) substitution in the C1-tetrahydrofolate synthase enzyme, a trifunctional protein essential for the interconversion of folate derivatives.

Clinical and metabolic evidence

The rs2236225 variant is primarily associated with clinical outcomes linked to folate metabolism rather than universal systemic homocysteine elevation. While large-scale human observational data showing a direct, consistent correlation with plasma homocysteine (p-tHcy) in healthy general populations are sometimes inconsistent, the variant's functional impact is well-documented:

• Disease associations: The 1958A allele is strongly associated with an increased risk for folate-sensitive conditions, such as neural tube defects, congenital heart defects, and cleft lip/palate, particularly in specific cohorts (e.g., North Indian and Irish populations).
• Nutritional interactions: The metabolic effects of this variant appear highly sensitive to nutritional context. The impairment in folate flux and subsequent homocysteine elevation may only become clinically detectable or significant in individuals with low dietary folate intake or those with other compounding genetic variants in the one-carbon pathway.

Mechanistic explanations

The MTHFD1 enzyme catalyzes three sequential reactions: the conversion of formate to 10-formyl-THF, the interconversion of 10-formyl-THF and tetrahydrofolate, and the formation of 5,10-methenyl-THF from 5,10-methylene-THF.

• Enzymatic destabilization: The R653Q substitution occurs in the synthetase domain of the enzyme. Evidence indicates that this change reduces protein stability and overall enzymatic activity.
• Metabolic flux disruption: Research in animal models shows that reduced MTHFD1 activity significantly perturbs one-carbon metabolism, leading to a marked increase in plasma homocysteine (p=0.0016) and a reduction in methionine and choline oxidation markers. This confirms that when enzyme function is compromised—as is the case with the rs2236225 variant—the cycle's ability to remethylate homocysteine is impaired.

Bottom line

The MTHFD1 rs2236225 variant reduces the enzyme's stability and capacity to interconvert folate forms. While its impact on systemic homocysteine levels can vary depending on population and folate status, it is mechanistically linked to impaired one-carbon flux and is a recognized risk factor for several folate-dependent developmental conditions.